MAPT and early-onset autosomal dominant Alzheimer disease: Amyloid-β (Aβ) 1-42, total tau (t-tau), and phosphorylated tau (p-tau) proteins in cerebrospinal fluid (CSF) are well-established biomarkers for Alzheimer’s disease (AD) [1]–[3], and are increasingly being used for diagnosis in clinical practice.